Skip to content

Comparison of the efficacy of amisulpride and aprepitant for the rescue treatment of postoperative nausea and vomiting in the PACU: A randomized controlled trial

Comparison of the efficacy of amisulpride and aprepitant for the rescue treatment of postoperative nausea and vomiting in the PACU: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119505
Enrollment
Unknown
Registered
2026-02-28
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Interventions

Amisulpride group:In the event of PONV occurring in the PACU, amisulpride injection 10 mg (diluted to 20 mL with normal saline) was administered slowly by intravenous injection.
Aprepitant group:In the event of PONV occurring in the PACU, aprepitant injection 32 mg (diluted to 20 mL with normal saline) was administered slowly by intravenous injection.
Combination therapy group of aripipitan and amisulpride:In the event of PONV occurring in the PACU, aprepitant injection 32 mg (diluted to 20 mL with normal saline) and amisulpride injection 10 mg (di

Sponsors

Central Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, undergoing general anesthesia surgery; 2. ASA classification I-III; 3. Operation duration >=1 hour; 4. Occurrence of PONV in PACU postoperatively.

Exclusion criteria

Exclusion criteria: 1. Severe liver and kidney dysfunction, acute phase of gastrointestinal bleeding, history of arrhythmia; 2. Preoperative use of known antiemetic drugs, or presence of contraindications; 3. Presence of mental disorders or communication disorders; 4. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Postoperative nausea and vomiting 30-minute complete remission rate;

Secondary

MeasureTime frame
Extent of PONV relief at multiple time points (1h, 2h, 4h, 6h, 24h);Adverse events following treatment administration;Intraoperative opioid consumption;Postoperative NRS pain score;Number of rescue analgesia requests;Total dose of rescue analgesics administered;Postoperative quality of recovery (QoR-15 score); Patient satisfaction score (0-10 scale);

Countries

China

Contacts

Public ContactFanjun Meng

Central Hospital Affiliated to Shandong First Medical University

mfja@sina.com+86 153 1881 6233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026